Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
09/2005
09/29/2005US20050215553 For therapy and prophylaxis of cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers
09/29/2005US20050215549 TACE inhibitors
09/29/2005US20050215542 Compounds for the treatment of diseases
09/29/2005US20050215539 Derivatives of 1,2,3,5-tetrahydro-1-benzazepine, and 1,2,3,5-tetrahydro-4,1-benzoxazepine, benzthiazepine, and benzodiazepine: 4-methyl-5-(5-methyl-2-oxo-5-phenyl-1,2,3,5-tetrahydro-4,1-benzoxazepin-7-yl)thiophene-2-carbonitrile; contraceptives; hormone replacement therapy; antineoplastic agents
09/29/2005US20050215513 Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound
09/29/2005US20050214875 Metal chelate containing compositions for use in chemiluminescent assays
09/29/2005DE102004012365A1 Substituierte Dihydropyridine Substituted dihydropyridines
09/29/2005CA2560286A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005CA2559919A1 Sulphonamide derivatives
09/29/2005CA2559553A1 Ether derivatives, their manufacture and use as pharmaceutical agents
09/29/2005CA2559105A1 Benzisoxazoles
09/29/2005CA2558058A1 N-piperidine derivates as ccr3 modulators
09/29/2005CA2557929A1 Benzodiazepines for treating or preventing or preventing rsv infection
09/29/2005CA2557730A1 Novel heterocyclyl-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
09/29/2005CA2557054A1 (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor
09/29/2005CA2554610A1 Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
09/29/2005CA2554609A1 Derivatives of heteroaryl-alkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors
09/28/2005EP1578746A1 Oxazoles as mglur1 enhancer
09/28/2005EP1578745A1 Benzofuran derivates, process for their preparation and intermediates thereof
09/28/2005EP1578744A1 Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
09/28/2005EP1578736A1 Mek inhibiting oxa- and thia-diazol-2-yl-phenylamine derivatives
09/28/2005EP1578734A1 Novel antibacterial agents
09/28/2005EP1578732A2 Pyrimidine derivatives for the treatment of abnormal cell growth
09/28/2005EP1578726A2 Tetrahydroquinoline derivatives
09/28/2005EP1578723A2 Process for the preparation of oxazolidinones and method of use thereof
09/28/2005EP1578425A1 Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
09/28/2005EP1578423A1 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
09/28/2005EP1373258B1 Ether derivatives useful as inhibitors of pde4 isozymes
09/28/2005EP1366029B1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents
09/28/2005EP1286987B1 Heterocyclic hydrazones for use as anti-cancer agents
09/28/2005EP1163227B1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
09/28/2005CN1675201A N-substituted piperidine derivatives as serotonin receptor agents
09/28/2005CN1675198A Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2a receptor-related disorders
09/28/2005CN1675197A 2-thio-substituted imidazole derivatives and their use in pharmaceutics
09/28/2005CN1675196A Indole derivatives or benzimidazole derivatives for modulating IKB kinase
09/28/2005CN1674906A 有丝分裂驱动蛋白抑制剂 Mitotic kinesin inhibitors
09/28/2005CN1674899A Use of IkappaB-kinase inhibitors in pain therapy
09/28/2005CN1674893A 苯并咪唑衍生物 Benzimidazole derivatives
09/28/2005CN1674892A Hetero biaryl derivatives as matrix metalloproteinase inhibitors
09/28/2005CN1673221A Isoxazoline derivative and herbicide comprising the same as active ingredient
09/28/2005CN1220684C 2, 4, Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
09/28/2005CN1220683C Acyl derivatives for treating VLA-4 related disorders
09/27/2005US6949653 A chemical intermediate reaction by starting 2,6-diaminopyridine with malic acid and sulfuric acid, salt formation, hydroxylation, chlorination, dehydroxylation, reduction, esterification
09/27/2005US6949578 useful in selectively inhibiting or antagonizing the alpha v beta 3 and/or alpha v beta 5 integrins; treatment of osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), angiogenesis
09/27/2005US6949571 Novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof.
09/27/2005US6949568 Such as N-(2-(4-(3-phenyl-4-methoxyphenyl)aminophenyl)ethyl)-2-hydroxy-2-(3 -hydroxymethyl-4-hydroxyphenyl)ethylamine; for treatment of chronic obstructive pulmonary disease
09/27/2005US6949566 For use as metalloproteinase inhibitors
09/27/2005US6949551 Dihalopropene compounds, processes for their preparation, compositions comprising them and their use as pesticides
09/27/2005US6949550 Substituted amino methyl factor Xa inhibitors
09/27/2005US6949546 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
09/27/2005US6949544 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
09/27/2005US6949540 Substituted pyrazoles
09/27/2005US6949537 LY294002 and analogs thereof comprising a reversibly quaternized amine; use of the pro-compounds for treatment of a condition associated with PI-3 kinase activity, including inflammatory disease, age-related macular degeneration, hypertension
09/22/2005WO2005087764A1 Tetrahydrobenzazepine derivatives as modulators of dopamine d3 receptors (antipsychotic agents)
09/22/2005WO2005087754A1 Substituted morpholine and thiomorpholine derivatives
09/22/2005WO2005087752A2 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005WO2005087750A1 Ion channel modulators
09/22/2005WO2005087749A1 2-aminoquinazoline derivative
09/22/2005WO2005087746A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders
09/22/2005WO2005087740A1 Fluorenone 1, 4,-dihydropyridin derivatives
09/22/2005WO2005086898A2 Inhibitors of histone deacetylase
09/22/2005WO2005086892A2 Ion channel modulators
09/22/2005WO2005056547A3 Quinoxalines useful as inhibitors of protein kinases
09/22/2005WO2005016876A3 Cyclic amine bace-1 inhibitors having a benzamide substituent
09/22/2005US20050209456 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents
09/22/2005US20050209290 Novel ether derivatives
09/22/2005US20050209284 Tec kinase inhibitors
09/22/2005US20050209282 Inhibitors of voltage-gated sodium channels; acute, chronic, neuropathic, or inflammatory pain such as femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia
09/22/2005US20050209278 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
09/22/2005US20050209275 Beta 2-adrenergic receptor agonists
09/22/2005US20050209274 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
09/22/2005US20050209273 Neuroprotectants, analgesics or anticonvulsants
09/22/2005US20050209260 Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine
09/22/2005US20050209248 Plymorphic forms of phenyl oxazolidinone derivatives
09/22/2005US20050209247 Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors
09/22/2005US20050209233 Neuropeptide Y5 (NPY-5) receptor antagonists or agonists; eating disorders, diabetes dyslipidemia, hypertension, and sleep disorders; pyridazin-3-ylamino-substituted dibenzothiophenes and S-oxides thereof
09/22/2005US20050209232 Useful for treating inflammatory, immunological, and integrin-mediated disorders such as inflammatory bowel disease; 2-(3,3-Diisopropyl-ureido)-3-[4-(5-methoxy-2-methyl-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-propionic acid for example
09/22/2005US20050209231 In embryonic stem cells in vitro and in vivo; cardiomyopathy; 2,6-diaminopyrimidine compounds
09/22/2005US20050209230 2,4-Pyrimidinediamine compounds and their uses
09/22/2005US20050209228 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
09/22/2005US20050209226 Tetrahydroquinoline analogues as muscarinic agonists
09/22/2005US20050209224 N4-(4H-5-pyrid[1,4]oxazin-6-yl)-2,4-pyrimidinediamine derivatives; for treating rheumatoid arthritis
09/22/2005US20050209223 N-(p-(substituted 1,2,3-triazol-1-yl)phenyl) derivatives of cycloazaalkanes; particularly useful for treating methicillin-resistant Staphylococcus aureas infections
09/22/2005US20050209195 Derivatives of compound 1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one; Antitumor agents; tyrosine kinase inhibitors
09/22/2005US20050209164 Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
09/22/2005US20050208582 Pyrazole compounds and pharmaceutical compositions comprising the compound
09/22/2005US20050208534 Methine-substituted cyanine dye compounds
09/22/2005US20050207996 Use of osteopontin in dental formulations
09/22/2005DE10100772B4 Ether- und Amidverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antidiabetika Ether and amide compounds, processes for their preparation and their use as antidiabetic agents
09/22/2005CA2560098A1 2-aminoquinazoline derivative
09/22/2005CA2558243A1 Inhibitors of histone deacetylase
09/22/2005CA2558224A1 Ion channel modulators
09/22/2005CA2558036A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2558034A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2557904A1 Hiv integrase inhibitors
09/22/2005CA2557642A1 Ion channel modulators
09/21/2005EP1577305A1 Oral antidiabetic agents
09/21/2005EP1577302A1 Novel ethylenediamine derivatives
09/21/2005EP1577301A1 Diamine derivatives
09/21/2005EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
1 ... 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 ... 647